Decoding the host immune response into simple diagnostic insights
Timely assessment of patients presenting with infection in the Emergency Department improves outcomes, patient management, and antibiotic stewardship while reducing hospital costs. At MeMed, we decode the body’s complex host response to provide clinicians with actionable insights that improve patient care.
The FDA-cleared and CE-Marked MeMed BV®, our flagship product, accurately differentiates bacterial from viral infection within 15 minutes from serum while the CE-Marked MeMed COVID-19 Severity™ meets the urgent need of risk-stratifying COVID-19 patients.*
MeMed’s tests run on the MeMed Key®, an FDA-cleared, compact immunoassay platform that delivers results of these novel tests in just 15 minutes from serum.
Additional diagnostic applications, focused on critical, unmet needs in healthcare, are currently in development, all designed to support clinicians in making informed and timely decisions.
MeMed BV and MeMed Key are FDA, CE-IVD and AMAR cleared and available in the US, EU, and Israel. MeMed COVID-19 Severity is CE-IVD and AMAR cleared and available in the EU and Israel. *MeMed COVID-19 Severity is not cleared by the FDA for any indication, and is not available for sale in the US.
Designed to deliver results in just 15 minutes from serum.